The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157: Miracle Healing Peptide or Hidden Danger? FDA to Remove 12 Popular Peptides from the Category 2 Do Not Compound List Frier Levitt FDA Peptide Update 2026: Removal from Do Not Compound List and What It Means for Pharmacies FDA to weigh easing limits on unproven peptides promoted by RFK Jr. Compounding warning letters to 503A facilities between 2017 and 2021 Journal of the American Pharmacists Association FDA Sends 30 Warning Letters To Continue Clampdown on Compounded GLP 1s BioSpace